there are companies working on commercializing phage therapy, though often for rare disease or cancer. developing new antibiotics in general is difficult in th

there are companies working on commercializing phage therapy, though often for rare disease or cancer. developing new antibiotics in general is difficult in the US because there are many generic antibiotics that work well, so your pricing power is often quite low. but your R&D costs are still just as high as something like cancer, where you can charge hundreds of thousands a year per patient. so R&D dollars go to higher ROI assets. see novartis, which recently axed its antibiotics division super resistant bugs are a big issue however and there is probably an investment case there, esp at a time like this when capital is so available. i dont know how hard it would be to develop drugs against particular resistant strains, how many patients get each infection / year, how long you have to intervene before pts die, etc, but i can imagine its a tough field